We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer.
- Authors
Chen, F.; Hu, P.; Liang, N.; Xie, J.; Yu, S.; Tian, T.; Zhang, Jingxin; Deng, G.; Zhang, Jiandong
- Abstract
Purpose: We conduct this study to compare the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) concurrent weekly nedaplatin (NDP) versus IMRT alone in the stage III/IV non-surgical elderly patients with non-small-cell lung cancer (NSCLC).Methods: 117 patients were enrolled into our study. The patients were assigned into two different groups: radiotherapy (RT) group and chemoradiotherapy (CRT) group. Patients in RT group were treated with IMRT at a single daily dose of 2 Gy for 5 days per week, totally 52–66 Gy. The CRT group, IMRT concurrent weekly NDP at a dose of 25 mg/m2.Results: In CRT group, the median survival was 11.0 months (95% confidence interval [CI], 8.894–13.106 months) and in RT group, it was 7.0 months (95% CI 5.771–8.229 months). The 1-year, 2-year, 3-year, survival rates in the combined treatment arm were higher than the radiation therapy arm (46.8 vs 25.9%, 25.1 vs 11.8%, 14.7 vs 8.0%; <italic>p</italic> < 0.001). The Cox’s multiple regression analysis showed that CRT had significantly better overall survival than RT (HR 0.523; 95.0% CI 0.338–0.807; <italic>p</italic> = 0.003). The objective response rate provided that 73.3% treated with CRT compared with 51.1% (<italic>p</italic> = 0.018) received RT alone. Of the hematologic toxicities, leukocytes (35.0 vs 0%; <italic>p</italic> < 0.001), neutrophils (33.3 vs 0%; <italic>p</italic> < 0.001) were significantly more common in the CRT group than the RT group.Conclusions: We first discovered that NDP concurrent IMRT for treating stage III/IV non-surgical elderly patients with NSCLC was good curative effect of better objective response rate and well-tolerated. However, within the low number of patients, only stage IV gained a survival benefit.
- Publication
Clinical & Translational Oncology, 2018, Vol 20, Issue 3, p294
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-017-1716-0